eXoZymes, Inc. (EXOZ)
| Market Cap | 137.98M |
| Revenue (ttm) | -700 |
| Net Income (ttm) | -5.12M |
| Shares Out | 9.53M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,467 |
| Open | 15.40 |
| Previous Close | 14.43 |
| Day's Range | 14.15 - 15.40 |
| 52-Week Range | 8.50 - 23.99 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 18, 2025 |
About EXOZ
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. The company was founded in 2014 and is headquarter... [Read more]
Financial Performance
In 2023, eXoZymes's revenue was $70,069, an increase of 145.01% compared to the previous year's $28,598. Losses were -$2.04 million, 46.0% more than in 2022.
Financial StatementsNews
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc.
Monrovia, CA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ, formerly Invizyne Technologies) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essentia...